Neil Lindsay Berkley Sells 19,360 Shares of Alector (NASDAQ:ALEC) Stock

Alector, Inc. (NASDAQ:ALEC) CFO Neil Lindsay Berkley sold 19,360 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $1.97, for a total value of $38,139.20. Following the sale, the chief financial officer directly owned 379,900 shares in the company, valued at approximately $748,403. This trade represents a 4.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Alector Trading Up 2.0%

NASDAQ ALEC opened at $1.81 on Friday. The company has a quick ratio of 5.25, a current ratio of 5.25 and a debt-to-equity ratio of 0.80. Alector, Inc. has a twelve month low of $1.09 and a twelve month high of $3.40. The company has a market cap of $200.96 million, a price-to-earnings ratio of -1.52 and a beta of 0.61. The business’s fifty day moving average is $2.28 and its 200 day moving average is $1.94.

Alector (NASDAQ:ALEC) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.08. Alector had a negative return on equity of 295.17% and a negative net margin of 680.83%.The company had revenue of $1.05 million for the quarter, compared to the consensus estimate of $9.67 million. As a group, sell-side analysts expect that Alector, Inc. will post -0.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ALEC has been the topic of several recent research reports. Wall Street Zen raised Alector from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Morgan Stanley reissued an “underweight” rating and set a $2.00 price objective on shares of Alector in a report on Monday, May 4th. BTIG Research raised Alector from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a research report on Tuesday, March 10th. Cantor Fitzgerald raised Alector from a “neutral” rating to an “overweight” rating in a research report on Wednesday, April 15th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alector in a research report on Monday, May 4th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $3.63.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ALEC. Lexington Partners L.P. bought a new position in Alector during the 3rd quarter worth $30,000. Bronte Capital Management Pty Ltd. bought a new position in Alector during the 4th quarter worth $30,000. Prudential Financial Inc. bought a new position in Alector during the 2nd quarter worth $30,000. Hershey Trust Co. raised its position in Alector by 100.0% during the 4th quarter. Hershey Trust Co. now owns 20,572 shares of the company’s stock worth $32,000 after purchasing an additional 10,286 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Alector during the 4th quarter worth $34,000. 85.83% of the stock is owned by institutional investors.

About Alector

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.